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with a high risk of cardiovascular morbidity among an
unselected population undergoing LVRS.2 Although
there is agreement that patients should be evaluated pre-
operatively for high-risk cardiovascular disease,1,2 there
is currently no consensus with respect to specific pre-
operative testing before LVRS.
Dobutamine stress echocardiography (DSE) is an
Lung volume reduction surgery (LVRS) is currentlyundergoing evaluation as a bridge to lung transplan-
tation and as definitive therapy for advanced chronic
obstructive lung disease.1 However, the prevalence of
coronary artery disease (CAD) and of pulmonary
hypertension among patients with a history of tobacco
use and severe obstructive lung disease are associated
Background: Lung volume reduction surgery has been proposed as a
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We investigated the feasibility, safety, and value of dobutamine stress
echocardiography as a predictor of major early cardiac events in patients
who underwent lung volume reduction surgery. Methods: The study pop-
ulation consisted of 46 patients (21 men and 25 women, mean age 59 ± 9
years) who underwent dobutamine stress echocardiography (maximum
dose 40 µg · kg–1 · min–1 plus atropine if needed) 180 days or less before
lung volume reduction surgery. Adverse cardiac events were prospective-
ly defined and tabulated during hospitalization after the operation and at
subsequent outpatient visits. Results: Dobutamine stress echocardiogra-
phy was interpretable in 45 of 46 (98%) patients. There were no adverse
events during testing. The studies revealed normal left ventricular sys-
tolic function at rest in all patients and normal right ventricular function
in all patients but one. Thirteen patients had right ventricular enlarge-
ment. Estimated right ventricular systolic pressure was mildly elevated
(>40 mm Hg) in 5 patients. Four patients (9%) had stress tests positive
for ischemia. There were no perioperative deaths. Follow-up was avail-
able for 44 of 45 patients at a duration of 20.0 ± 7.0 months. Two major
adverse cardiac events occurred in the same patient in whom the results
of dobutamine stress echocardiography were positive for ischemia (posi-
tive predictive value 25%, 95% confidence interval 0% to 83%; negative
predictive value 100%, 95% confidence interval 90 to 100%). Conclusion:
Despite end-stage chronic obstructive lung disease and poor ultrasound
windows, dobutamine stress echocardiography is feasible and safe in
patients undergoing evaluation for lung volume reduction surgery. It
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has an excellent negative predictive value for early and late adverse car-
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accepted means for the evaluation of inducible
ischemia3,4 and for the assessment of perioperative
risk.5-7 In addition, echocardiography can be used to
assess both left and right ventricular systolic function,
evaluate the presence and severity of valvular heart dis-
ease, and estimate right ventricular systolic pressure.8,9
The presence of severe obstructive lung disease may
compromise echocardiographic windows and may
result in suboptimal image quality in this population.
The purpose of the present study was to evaluate the
feasibility, safety, and prognostic value of DSE in a
group of patients undergoing LVRS.
Methods
Study population. The study population consisted of 46
consecutive patients who underwent DSE at the University of
Michigan 180 days or less before LVRS during 1995 and
1996. The average time between DSE and LVRS was 77 ± 41
days (range 8-179 days).
Cardiac risk profile. Risk factors for CAD or a known his-
tory of CAD were prospectively investigated during preoper-
ative clinical assessment. Risk factors included family history
of CAD, systemic hypertension, diabetes mellitus, hypercho-
lesterolemia, and recent tobacco use. Of note, nearly all
patients had a history of tobacco use at some time in the past,
but it was reported only if recent.
Imaging protocol. Echocardiographic imaging was per-
formed with standard, commercially available equipment.
Imaging included visualization of left- and right-sided car-
diac chambers and valves for evaluation of left and right ven-
tricular size and function, as well as for evidence of valvular
heart disease. In addition to the assessment of ventricular
function and valvular heart disease at baseline, right ventric-
ular systolic pressure was estimated from the spectral profile
of the tricuspid regurgitation jet. The right ventricular systolic
pressure was calculated by adding a fixed value of 14 mm Hg
(assumed right atrial pressure) to the systolic transtricuspid
gradient (D P = 4 · V2, where V = maximum velocity of tri-
cuspid regurgitation).8-11 In accordance with routine laborato-
ry practice, contrast injection was not routinely used for
enhancement of the tricuspid regurgitation envelope.
Pulmonary hypertension was defined as any right ventricular
systolic pressure greater than 40 mm Hg.
Dobutamine protocol. DSE was performed as previously
described.4 Antianginal medications were not withheld before
testing. Windows were used during echocardiographic imag-
ing to optimize visualization of left ventricular wall motion
and systolic function. Imaging typically included parasternal
long- and short-axis, apical 4- and 2-chamber, and subcostal
views. Dobutamine was infused in 3-minute stages of 10, 20,
30, and 40 m g · kg–1 · min–1. Atropine was administered in
0.25 mg boluses up to 1.0 mg total dose if the heart rate was
less than 100 beats/min at 30 m g · kg–1 · min–1. Blood pres-
sure, 12-lead electrocardiograms, and echocardiograms were
recorded during each stage and at 10 minutes of recovery. All
echocardiographic images were recorded on standard VHS
videotape. In addition, echocardiographic images at baseline,
low stress (10 mg · kg–1 · min–1), peak stress, and recovery
were digitized and displayed in quad-screen format for sub-
sequent off-line analysis. The left ventricle was analyzed with
the use of a 16-segment model.12,13 Wall motion score index
(WMSI) was calculated at rest and peak dobutamine stress
with the use of a standard formula in which normal = 1,
hypokinesia = 2, akinesia = 3, and dyskinesia = 4. Ischemia
was defined as the development of a new or worsening wall
motion abnormality during stress. Tests were interpreted by
experienced echocardiographers at the time of performance.
Reviewers were blinded to clinical information and to the
results of any other cardiac tests. The protocol for DSE was
reviewed and approved by the University of Michigan
Institutional Review Board. All patients provided written
informed consent.
Clinical follow-up. Patients were monitored during hospi-
talization and returned after discharge for regular follow-up
visits. Cardiac events were prospectively defined on the basis
of standard clinical definitions, recorded at the time of occur-
rence and subsequently compiled by retrospective review.
Major cardiac events were considered to be cardiac death,
nonfatal myocardial infarction, congestive heart failure, and
unstable angina pectoris necessitating hospitalization. Minor
cardiac events included atrial fibrillation, other supraventric-
ular tachycardia, or hypotension.
Statistics. All data are presented as mean ± 1 standard
deviation. Comparison of hemodynamics at baseline and
peak stress were made by means of the paired Student t tests.
Results
Study population demographics are outlined in Table
I. At least 1 risk factor for CAD was present in 34
patients (74%), with 2 or more risk factors present in 12
patients (26%). Tobacco use was by far the most preva-
lent risk factor, followed by hypertension, known CAD,
and then hyperlipidemia and family history of CAD.
Feasibility and safety. Of 46 patients who under-
went both DSE and subsequent LVRS, 45 (98%) had
echocardiography/Doppler images adequate for analy-
sis. Assessment of left ventricular wall motion for
ischemia was performed in all of the 45 patients who
underwent DSE.
DSE was well tolerated. The most frequent side
effects were minor and included palpitations in 38
patients (84%), of whom 11 (29%) had shortness of
breath and 1 had nausea. No patient had angina, signif-
icant ventricular or supraventricular arrhythmias, or
myocardial infarction.
Resting echocardiography. Of 45 echocardiograph-
ic examinations, 19 (42%) were completely normal
with no evidence of valve disease and normal left- and
right-sided chamber size and function. A total of 43
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echocardiographic or Doppler abnormalities were
noted among the remaining 26 patients, of which 33
(78%) were associated with the right side of the heart
and 10 (23%) with the left side of the heart. The
Doppler signal of tricuspid regurgitation was adequate
for the estimation of right ventricular systolic pressure
in 35 (76%) patients, of whom 30 (86%) had a right
ventricular systolic pressure of 40 mm Hg or less and 5
(14%) had a pressure of more than 40 mm Hg. Of the
5 patients with a right ventricular systolic pressure of
more than 40 mm Hg, the average estimated pressure
was 56 ± 12 mm Hg (range 41-70 mm Hg). Mild pul-
monary hypertension was confirmed on right heart
catheterization in all 5 of these patients (pulmonary
artery systolic pressure 41.8 ± 5.4 mm Hg). Table II
summarizes the 2-dimensional echocardiographic
abnormalities noted among all patients.
DSE. The hemodynamic changes with dobutamine
are shown in Table III. Two patients had abnormal wall
motion at baseline. For these 2 patients, WMSI at base-
line was 2.09 and 2.31, respectively. DSE revealed
inducible ischemia in 4 of 45 patients (9%), including
both patients with abnormal wall motion at baseline.
For the 2 patients with abnormal wall motion at base-
line, WMSI increased with dobutamine from 2.09 and
2.31 to 2.28 and 2.63, respectively. WMSI for the 4
patients with inducible ischemia increased from 1.6 ±
0.7 (range 1.0-2.3) to 1.8 ± 0.7 (range 1.1-2.6), with
stress (D = 0.2 ± 0.1; range 0.1-0.3). For the remaining
42 patients, WMSI remained 1.0 at peak stress (normal
response).
Outcome. Clinical data were available for all
patients during their hospitalization after the operation.
The average length of hospital stay after LVRS was 11
± 6 days (range 5-25 days). No patient died during the
operation or during the subsequent hospitalization.
Similarly, no patients had acute myocardial infarction
or unstable angina in the operative or perioperative
period. A single episode of pulmonary edema occurred
in 1 of the 4 patients with ischemia on DSE. Two other
patients had minor cardiac events. One patient with
normal DSE test results had paroxysmal atrial fibrilla-
tion develop; another patient with abnormal DSE test
results had episodes of supraventricular tachycardia
with hypotension. Both arrhythmias resolved with
appropriate therapy. On the basis of the single major
event among 4 patients with ischemia on DSE, there
was a positive predictive value for DSE in predicting
major perioperative events of 25% (95% CI 0%-83%).
No patient with a negative DSE test result had any
major cardiac complication, yielding a negative predic-
tive value for major cardiac events of 100% (95% CI
90%-100%).
Follow-up after discharge was available for 44 of 45
patients (98%) at a duration of 20.0 ± 7.0 months
(range 4-31 months) after the operation. Follow-up was
Table I. Population demographics
Total Unilateral Bilateral
LVRS 46 7 (15%) 39 (85%)
Age (y)
Mean ± SD (range) 59 ± 9 (38-74) 50 ± 11 61 ± 7
Sex (M/F) 21/25 (46%/54%) 4/3 18/21
Diagnosis
Emphysema 45 (98%) 6 39
A1AT 1 (2%) 1 0
CAD risk factors
Recent tobacco use 30 (65%)
Hypertension 9 (19%)
Cholesterol > 200 1 (2%)
mg/dL
Family history of 1 (2%)
CAD
Diabetes 0
Known CAD 4 (9%)
A1AT, Alpha-1 antitrypsin deficiency; LVRS, lung volume reduction surgery.
Table II. Resting 2-dimensional echocardiographic
abnormalities
No. %
Dilated left ventricle 2 4
Dilated right ventricle 13 29
Dilated left atrium 4 9
Dilated right atrium 9 20
Left ventricular hypertrophy 1 2
Right ventricular hypertrophy 2 4
Wall motion abnormalities at rest 2 4
Right ventricular dysfunction 1 2
Flattened septum with pressure overload 8 18
Valvular heart disease 1 2
Table III. Hemodynamic changes with dobutamine
Baseline Peak D P value
Heart rate 
(beats/min)
Mean ± SD 78 ± 13 121 ± 15 43.3 ± 13.2 < .001
Range 51 to 111 85 to 170 19 to 88
Systolic blood 
pressure (mm Hg)
Mean ± SD 132 ± 13 128 ± 18 –5.2 ± 18.7 .1
Range 106 to 159 91 to 172 –43 to +35
Diastolic blood 
pressure (mm Hg)
Mean ± SD 73 ± 9 65 ± 15 –7.6 ± 15.4 .001
Range 56 to 94 43 to 107 –44 to +40
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6 months or more for 43 of 45 patients (96%) and more
than 1 year for 39 of 45 (87%). During long-term fol-
low-up there were no major cardiac events. One
episode of pulmonary edema and 1 episode of paroxys-
mal atrial fibrillation occurred in the same 2 patients
who experienced these complications during hospital-
ization. One additional patient with a negative DSE test
result had atrial flutter in the follow-up period. Table IV
summarizes DSE results and prognosis for those
patients with either an abnormal DSE suggestive of
ischemia or any early or late cardiac event.
Discussion
DSE is an accepted technique for the preoperative
assessment of cardiac risk in patients undergoing non-
cardiac surgery.14-23 Several studies have demonstrated
the feasibility, safety, and prognostic value of DSE for
perioperative and late cardiac events in both vascular
surgery14-22 and general surgical procedures.23 Because
candidates for LVRS are frequently former heavy smok-
ers with a presumed high prevalence of cor pulmonale
and CAD,2 surgical morbidity has been found to be pro-
hibitive in unselected populations.1,24,25 Limitations in
exercise capacity resulting from underlying advanced
lung disease make pharmacologic stress testing an ideal
tool to assess these patients for occult CAD and
inducible ischemia. Although nuclear scintigraphy
allows assessment for CAD, echocardiography also
allows for the assessment of left and right ventricular
systolic function, valvular heart disease, and evidence of
pulmonary hypertension. However, echocardiographic
windows are affected by hyperexpansion of lung
parenchyma, and acoustic windows may be limited in
this patient population. The present study is the first to
our knowledge to address the feasibility and the prog-
nostic power of DSE in a surgical population limited to
patients with end-stage obstructive lung disease under-
going a major intrathoracic procedure.
Feasibility and safety. In the present study, DSE was
feasible in 98% (45/46) of patients, despite the pres-
ence of end-stage lung disease in all of them. Even
though these patients had significant comorbid disease,
DSE was found to have a safety profile similar to that
noted in other patient populations.14-23
Predictive power. DSE was found to have an excel-
lent negative predictive value for early and late cardiac
events, which appears to be comparable with that found
for other types of noncardiac surgery.14-23 In particular,
for patients undergoing vascular surgery, the negative
predictive value of dobutamine-atropine stress echocar-
diography for perioperative and late cardiac events
ranges from 95% to 100%.7 A high negative predictive
value of 94% was found as well by Bates and associ-
ates23 in patients with insulin-dependent diabetes mel-
litus before kidney and/or pancreas transplantation.
Limitations. Very few adverse cardiac events and no
major adverse events occurred in the surgical popula-
tion. However, this finding is reflective of the highly
selected nature of this population and the fact that
physicians were not blinded to the results of DSE.
Patients with clinically apparent cardiovascular abnor-
malities likely were not referred for subsequent
surgery. This is not a unique finding and it is in accor-
dance with the very low rate of cardiac complications
demonstrated by previous investigators in similar stud-
ies after patients have been appropriately screened for
surgery.2 In a study by Cooper and colleagues,26 only 4
of 150 (2.6%) consecutive patients had major cardiac
complications after bilateral LVRS, including 2 with
myocardial infarction and 2 with cardiac arrest.
Similarly, McKenna and coworkers27 found only 1
major in-hospital cardiac event after LVRS among 166
consecutive patients (0.6%). As noted earlier, the low
rate of perioperative events among the present and pre-
vious populations undergoing LVRS was likely due to
application of conservative selection criteria.
Table IV. Outcome for patients with abnormal DSE or adverse cardiac events
DSE
Cardiac events
Patient Risk factors Hospital Follow-up Preop RVSP WMSI WMSI WMSI
(age [y], sex) for CAD LVRS stay (d) (d) (mm Hg) Base Peak D Early Late
1 (64, M) Tob/HTN B 14 577 <40 1 1 0 0 A Flutter
2 (58, F) Tob B 8 556 <40 1 1 0 A Fib A Fib
3 (59, F) Tob/HTN B 24 810 <40 2.09 2.28 0.19 CHF CHF
4 (70, M) Tob/HTN/HL B 10 810 <40 1 1.06 0.06 SVT/Hypo 0
5 (59, F) CAD U 13 296 <40 2.31 2.63 0.32 0 0
6 (43, F) Tob/HTN U 5 506 <40 1 1.31 0.31 0 0
A Fib, Atrial fibrillation; A Flutter, atrial flutter; B, bilateral; CHF, congestive heart failure; HL, hyperlipidemia; HTN, hypertension; RVSP, right ventricular systolic
pressure (from echo); Tob, recent tobacco use; SVT/Hypo, supraventricular tachycardia with hypotension; U, unilateral; WMSI, wall motion score index.




DSE is safe and feasible for the preoperative assess-
ment of cardiac risk among candidates for LVRS. It
represents a highly versatile diagnostic tool that pro-
vides important information regarding left and right
ventricular systolic function, valvular heart disease,
and presence of CAD and inducible ischemia. A nega-
tive DSE test result implies low perioperative and sub-
sequent cardiac risk among patients referred for LVRS.
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